<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754104</url>
  </required_header>
  <id_info>
    <org_study_id>M10-371</org_study_id>
    <nct_id>NCT00754104</nct_id>
  </id_info>
  <brief_title>Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 7, 15, 21, 35 and Day 1 of every 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-869</intervention_name>
    <description>0.25 mg/kg. daily.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva</intervention_name>
    <description>150mg, daily.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have a histologically or cytologically confirmed non-hematologic&#xD;
             malignancy.&#xD;
&#xD;
          -  Subject must have an ECOG Score of 0-2.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has received targeted VEGF/PDGF therapy (tyrosine kinase inhibitor) therapy.&#xD;
             Prior Avastin allowed.&#xD;
&#xD;
          -  Subject has untreated brain or meningeal metastases.&#xD;
&#xD;
          -  History of greater than 10% weight loss.&#xD;
&#xD;
          -  Has clinically relevant hemoptysis.&#xD;
&#xD;
          -  Subject has proteinuria CTC grade &gt; 1.&#xD;
&#xD;
          -  Must not have had radiation therapy or major surgery within 21 days of study day 1.&#xD;
&#xD;
          -  The subject currently exhibits symptomatic or persistent, uncontrolled hypertension&#xD;
             defined as diastolic blood pressure (DBP) &gt; 100 mmHg or systolic blood pressure (SBP)&#xD;
             &gt; 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled&#xD;
             with or without intervention.&#xD;
&#xD;
          -  The subject has a documented left ventricular ejection fraction (LVEF) &lt; 50%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <last_update_submitted>January 17, 2011</last_update_submitted>
  <last_update_submitted_qc>January 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rod Humerickhouse, Global Project Head, Oncology</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

